Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219141 · ClinicalTrials.gov registry record · Phase 3
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
A Phase 3 study of Hypertension and Overweight, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
- 9
- Study locations
NCT00219141 is a Phase 3 study of Hypertension and Overweight that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 460 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 2 states.
The verdict
NCT00219141, a Phase 3 study of Hypertension and Overweight, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
- 9
- Study locations
Study Summary
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
Conditions Studied
Interventions
- DRUG Aliskiren 150/300 mg
- DRUG Losartan 50/100 mg
- DRUG Aliskiren placebo
- DRUG Losartan 50/100 mg placebo
Study Locations (9)
Other
- sites in Argentina - Argentina
- sites in Colombia - Colombia
- sites in Finland - Finland
- sites in Germany - Germany
- sites in Italy - Italy
- sites in Russia - Russia
- sites in Spain - Spain
- sites in Sweden - Sweden
New Jersey
- Novartis Pharmaceuticals - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219141
The ClinicalTrials.gov registry entry for NCT00219141 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Aliskiren 150/300 mg is the first listed.
NCT00219141 reports 9 study locations spanning 2 distinct geographic areas - top geographies include Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00219141 about?
NCT00219141 is a clinical study titled "Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension". To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
What is the current status of trial NCT00219141?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2005-10. Estimated completion is 2007-11.
What conditions does trial NCT00219141 study?
This clinical trial studies the following conditions: Hypertension, Overweight, Left Ventricular Hypertrophy.
What interventions are being tested in trial NCT00219141?
The interventions under investigation include: Aliskiren 150/300 mg (DRUG), Losartan 50/100 mg (DRUG), Aliskiren placebo (DRUG), Losartan 50/100 mg placebo (DRUG).
Who is sponsoring clinical trial NCT00219141?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219141 being conducted?
This trial has 9 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.